213 related articles for article (PubMed ID: 29324805)
1. Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses.
Lee YT; Ko EJ; Lee Y; Kim KH; Kim MC; Lee YN; Kang SM
PLoS One; 2018; 13(1):e0190868. PubMed ID: 29324805
[TBL] [Abstract][Full Text] [Related]
2. Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.
Kim MC; Lee JW; Choi HJ; Lee YN; Hwang HS; Lee J; Kim C; Lee JS; Montemagno C; Prausnitz MR; Kang SM
J Control Release; 2015 Jul; 210():208-16. PubMed ID: 26003039
[TBL] [Abstract][Full Text] [Related]
3. Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.
Lee YN; Kim MC; Lee YT; Kim YJ; Lee J; Kim C; Ha SH; Kang SM
Antiviral Res; 2015 Oct; 122():82-90. PubMed ID: 26248203
[TBL] [Abstract][Full Text] [Related]
4. Enhancing the cross protective efficacy of live attenuated influenza virus vaccine by supplemented vaccination with M2 ectodomain virus-like particles.
Lee YT; Kim KH; Ko EJ; Kim MC; Lee YN; Hwang HS; Lee Y; Jung YJ; Kim YJ; Santos J; Perez DR; Kang SM
Virology; 2019 Mar; 529():111-121. PubMed ID: 30685658
[TBL] [Abstract][Full Text] [Related]
5. Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination.
Lee YN; Lee YT; Kim MC; Hwang HS; Lee JS; Kim KH; Kang SM
Immunology; 2014 Oct; 143(2):300-9. PubMed ID: 24773389
[TBL] [Abstract][Full Text] [Related]
6. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity.
Kim MC; Lee YN; Hwang HS; Lee YT; Ko EJ; Jung YJ; Cho MK; Kim YJ; Lee JS; Ha SH; Kang SM
Vaccine; 2014 Oct; 32(44):5824-31. PubMed ID: 25171841
[TBL] [Abstract][Full Text] [Related]
7. Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection.
Kim MC; Lee YN; Ko EJ; Lee JS; Kwon YM; Hwang HS; Song JM; Song BM; Lee YJ; Choi JG; Kang HM; Quan FS; Compans RW; Kang SM
Mol Ther; 2014 Jul; 22(7):1364-1374. PubMed ID: 24590045
[TBL] [Abstract][Full Text] [Related]
8. Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.
Kim YJ; Kim KH; Ko EJ; Kim MC; Lee YN; Jung YJ; Lee YT; Kwon YM; Song JM; Kang SM
J Virol; 2018 Oct; 92(20):. PubMed ID: 30068650
[TBL] [Abstract][Full Text] [Related]
9. Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets.
Music N; Reber AJ; Kim MC; York IA; Kang SM
Vaccine; 2016 Jan; 34(4):466-473. PubMed ID: 26709639
[TBL] [Abstract][Full Text] [Related]
10. A Novel Vaccination Strategy Mediating the Induction of Lung-Resident Memory CD8 T Cells Confers Heterosubtypic Immunity against Future Pandemic Influenza Virus.
Lee YN; Lee YT; Kim MC; Gewirtz AT; Kang SM
J Immunol; 2016 Mar; 196(6):2637-45. PubMed ID: 26864033
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.
Xue C; Tian G; Chen X; Liu Q; Ma J; Xu S; Li X; Chen H; Cao Y
Virus Res; 2015 Jan; 195():35-42. PubMed ID: 25312452
[TBL] [Abstract][Full Text] [Related]
12. Influenza M2 virus-like particle vaccination enhances protection in combination with avian influenza HA VLPs.
Kang HJ; Chu KB; Lee DH; Lee SH; Park BR; Kim MC; Kang SM; Quan FS
PLoS One; 2019; 14(6):e0216871. PubMed ID: 31246961
[TBL] [Abstract][Full Text] [Related]
13. Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection.
Quan FS; Kim MC; Lee BJ; Song JM; Compans RW; Kang SM
Virology; 2012 Sep; 430(2):127-35. PubMed ID: 22658901
[TBL] [Abstract][Full Text] [Related]
14. Vaccine Efficacy Induced by 2009 Pandemic H1N1 Virus-Like Particles Differs from that Induced by Split Influenza Virus.
Lee GJ; Chu KB; Inn KS; Moon EK; Quan FS
Immunol Invest; 2020 Oct; 49(7):781-793. PubMed ID: 31774021
[TBL] [Abstract][Full Text] [Related]
15. Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.
Kamlangdee A; Kingstad-Bakke B; Osorio JE
J Virol; 2016 Aug; 90(15):6771-6783. PubMed ID: 27194759
[TBL] [Abstract][Full Text] [Related]
16. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection.
Tumpey TM; Renshaw M; Clements JD; Katz JM
J Virol; 2001 Jun; 75(11):5141-50. PubMed ID: 11333895
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
[TBL] [Abstract][Full Text] [Related]
18. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
[TBL] [Abstract][Full Text] [Related]
19. Cross-Protective Efficacy of Influenza Virus M2e Containing Virus-Like Particles Is Superior to Hemagglutinin Vaccines and Variable Depending on the Genetic Backgrounds of Mice.
Kim YJ; Lee YT; Kim MC; Lee YN; Kim KH; Ko EJ; Song JM; Kang SM
Front Immunol; 2017; 8():1730. PubMed ID: 29276514
[TBL] [Abstract][Full Text] [Related]
20. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
